Fluzone vaccine
Phase 1Vaccine
Fluzone vaccine is one of 52 vaccine programs targeting Atopic Dermatitis. It is currently in Phase 1.
2
Indications
3
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Focetria
CChiltern Pesquisa Clinica Ltda
Preclinical
Fluzone vaccine
CColby Pharmaceutical Company
Phase 1
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atopic Dermatitis1 trial
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT01737710·368 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fluzone vaccine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Vaccine[2]
- Highest Phase
- Phase 1[1]
- Company
- CColby Pharmaceutical Company